Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1994;3(5):341–346. doi: 10.1155/S0962935194000475

Autologous Enhancement by Interferon of Natural Killer Activity of Human Peripheral Blood Lymphocytes

S B Cheknev 1,✉, Y G Ashmanova 1, A D Pritsker 1, O L Latysheva 1, F I Yershov 1, A J Kulberg 1
PMCID: PMC2365580  PMID: 18475578

Abstract

The in vitro action of interferon (IFN)-α and IFN-γ from six healthy donors and ten patients with multiple sclerosis (MS) on natural killer (INK) activity of peripheral blood lymphocytes (PBL) was studied in an autologous system. The NK activity of PBL was detected by a cytotoxic test using 3H-uridine human erythromyeloblast K562 cells. Autologous IFN-α and IFN-γ did not augment NK activity of PBL from healthy donors in vitro, whereas in samples from MS patients the IFNs strongly stimulated NK cell cytotoxic function. This stimulation suggests the existence of an inhibitor of regulatory IFN action, that is produced in healthy donors simultaneously with IFN in response to IFN induction, but which is lacking in commercial IFN preparations. The factor-containing supernatants from healthy donors reduced the stimulatory action of autologous IFNs in patients with MS almost until complete blockade. Because this inhibitor was absent in patients with MS, deficiency of an inhibitor of IFN regulatory action in MS could open the way to treatment of this compartment of the immune system.

Full Text

The Full Text of this article is available as a PDF (553.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braakman E., van Tunen A., Meager A., Lucas C. J. Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit. Clin Exp Immunol. 1986 Nov;66(2):285–294. [PMC free article] [PubMed] [Google Scholar]
  2. Conte R., Dinota A., Tazzari P. L., Belletti D., Sermasi G. Analysis of natural killer cells in patients with idiopathic autoimmune hemolytic anemia. Vox Sang. 1989;56(4):270–273. doi: 10.1111/j.1423-0410.1989.tb02040.x. [DOI] [PubMed] [Google Scholar]
  3. Degré M., Dahl H., Vandvik B. Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders. Acta Neurol Scand. 1976 Feb;53(2):152–160. doi: 10.1111/j.1600-0404.1976.tb04333.x. [DOI] [PubMed] [Google Scholar]
  4. Fleischmann W. R., Jr, Georgiades J. A., Osborne L. C., Dianzani F., Johnson H. M. Induction of an inhibitor of interferon action in a mouse lymphokine preparation. Infect Immun. 1979 Dec;26(3):949–955. doi: 10.1128/iai.26.3.949-955.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Galvani D. W., Nethersell A. B., Cawley J. C. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells. Leuk Res. 1988;12(3):257–262. doi: 10.1016/0145-2126(88)90144-0. [DOI] [PubMed] [Google Scholar]
  6. Galvani D. W., Owens W., Nethersell A. B., Cawley J. C. The beneficial effects of alpha IFN in CGL are probably not mediated by NK cells. Br J Haematol. 1989 Feb;71(2):233–237. doi: 10.1111/j.1365-2141.1989.tb04260.x. [DOI] [PubMed] [Google Scholar]
  7. Grigorian S. S., Maiorov I. A., Ivanova A. M., Ershov F. I. Otsenka interferonovogo statusa liudei po probam tsel'noi krovi. Vopr Virusol. 1988 Jul-Aug;33(4):433–436. [PubMed] [Google Scholar]
  8. Hartung H. P., Heininger K. Non-specific mechanisms of inflammation and tissue damage in MS. Res Immunol. 1989 Feb;140(2):226–248. doi: 10.1016/0923-2494(89)90092-8. [DOI] [PubMed] [Google Scholar]
  9. Hashimoto Y., Sudo H. Evaluation of cell damage in immune reactions by release of radioactivity from 3 H-uridine labeled cells. Gan. 1971 Apr;62(2):139–143. [PubMed] [Google Scholar]
  10. Herberman R. B., Ortaldo J. R. Natural killer cells: their roles in defenses against disease. Science. 1981 Oct 2;214(4516):24–30. doi: 10.1126/science.7025208. [DOI] [PubMed] [Google Scholar]
  11. Hertzog P. J., Wright A., Harris G., Linnane A. W., Mackay I. R. Intermittent interferonemia and interferon responses in multiple sclerosis. Clin Immunol Immunopathol. 1991 Jan;58(1):18–32. doi: 10.1016/0090-1229(91)90145-z. [DOI] [PubMed] [Google Scholar]
  12. Kasahara T., Djeu J. Y., Dougherty S. F., Oppenheim J. J. Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor. J Immunol. 1983 Nov;131(5):2379–2385. [PubMed] [Google Scholar]
  13. Kirchner H., Kleinicke C., Digel W. A whole-blood technique for testing production of human interferon by leukocytes. J Immunol Methods. 1982;48(2):213–219. doi: 10.1016/0022-1759(82)90195-8. [DOI] [PubMed] [Google Scholar]
  14. Knobler R. L. Systemic interferon therapy of multiple sclerosis: the pros. Neurology. 1988 Jul;38(7 Suppl 2):58–61. [PubMed] [Google Scholar]
  15. Marchenko V. I., Pokidysheva L. N., Orlova N. G. Kriometod kontsentratsii interferona. Vopr Virusol. 1975 Sep-Oct;(5):568–570. [PubMed] [Google Scholar]
  16. McDonald W. I., Halliday A. M. Diagnosis and classification of multiple sclerosis. Br Med Bull. 1977 Jan;33(1):4–9. [PubMed] [Google Scholar]
  17. Neighbour P. A., Grayzel A. I., Miller A. E. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol. 1982 Jul;49(1):11–21. [PMC free article] [PubMed] [Google Scholar]
  18. Panitch H. S., Hirsch R. L., Haley A. S., Johnson K. P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987 Apr 18;1(8538):893–895. doi: 10.1016/s0140-6736(87)92863-7. [DOI] [PubMed] [Google Scholar]
  19. Solov'ev V. D., Bektemirov T. A. Leikotsitarnyi interferon--pokazatel' reaktivnosti organizma v norme i pri patologii. Vestn Akad Med Nauk SSSR. 1979;(2):19–26. [PubMed] [Google Scholar]
  20. Sorokin A. M., Chenëv S. B., Koval'chuk L. V. Rol' prilipaiushchikh kletok v obespechenii reaktsii estestvennoi tsitotoksichnosti. Biull Eksp Biol Med. 1989 Sep;108(9):322–325. [PubMed] [Google Scholar]
  21. Sorokin A. M., Koval'chuk L. V., Tunkel' O. I., Cheknev S. B. Interferonprodutsiruiushchaia i tsitotoksicheskaia aktivnost' estestvennykh kletok-killerov u bol'nykh rasseiannym sklerozom. Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(2):211–215. [PubMed] [Google Scholar]
  22. Targan S., Dorey F. Interferon activation of "pre-spontaneous killer" (pre-SK) cells and alteration in kinetics of lysis of both "pre-SK" and active SK cells. J Immunol. 1980 May;124(5):2157–2161. [PubMed] [Google Scholar]
  23. Uchida A., Maida E. M., Lenzhofer R., Micksche M. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis. Immunobiology. 1982 Feb;160(5):392–402. doi: 10.1016/S0171-2985(82)80003-X. [DOI] [PubMed] [Google Scholar]
  24. Whiteside T. L., Herberman R. B. The role of natural killer cells in human disease. Clin Immunol Immunopathol. 1989 Oct;53(1):1–23. doi: 10.1016/0090-1229(89)90096-2. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES